Key facts
- This page summarizes Alex Tarrabain's Form 4 filing for CEN BIOTECH INC.
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 25 Jun 2021, 17:04.
Alex Tarrabain - 25 Jun 2021 Form 4 Insider Report for CEN BIOTECH INC
- Reporting relationship
- Chief Financial Officer, Director
- Issuer ticker
- N/A
- Reported as of
- 25 Jun 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 25 Jun 2021, 17:04:05 UTC
- Prior SEC filing
- 03 Jun 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Alex Tarrabain
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Alex Tarrabain filed Form 4 for CEN BIOTECH INC on 25 Jun 2021.
Change
- Previous filing in this sequence was filed on 03 Jun 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CENBF
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +1,000,000
- Change %
- +56%
- Price
- $0.000000
- Shares after
- 2,775,942
- Date
- 25 Jun 2021
- Ownership
- Direct
- Footnotes
- F1
CENBF
transaction
Common Stock
Other
- Transaction value
- $0
- Shares
- +3,000
- Change %
- +0.11%
- Price
- $0.000000
- Shares after
- 2,775,942
- Date
- 16 Jun 2021
- Ownership
- Direct
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
1,000,000 shares of common stock of the issuer were granted by the issuer on June 25, 2021, pursuant to a restricted stock agreement pursuant to the issuer's equity compensation plan and the issuance was approved by the issuer's full board of directors.
Footnote F2
3,000 shares of common stock of the issuer were issued to the reporting person on June 16, 2021, as consideration for extending the maturity date of a promissory note dated January 14, 2018.